8-K current report · filed Nov 5, 2026

Teleflex Inc (TFX) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2TFX overview

Short answer

Teleflex Inc (TFX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1.

Teleflex Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1
  • Non-GAAP metrics emphasize pro forma revenue, constant-currency growth and adjusted diluted EPS
  • Pro forma results incorporate the BIOTRONIK Vascular Intervention acquisition as if completed January 1, 2025
  • Adjusted measures exclude restructuring, impairments, divestiture costs, amortization and Italian payback-related charges
  • Investors should compare GAAP results with adjusted figures, given extensive exclusions affecting underlying performance assessment

Item 7.01 · Regulation FD Disclosure

  • Slide presentation supports Teleflex’s November 5, 2026 conference call on third-quarter results
  • Results cover the quarter ended September 30, 2026
  • Investors should review Exhibit 99.2 for management’s financial and operating commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $567.8M, up 3.0% pro forma constant currency, with Vascular +4.6% and Surgical +5.1%
  • Adjusted EPS $2.63 versus $1.89, while adjusted operating margin reached 25.0%
  • 2026 adjusted EPS guidance raised to $7.50-$7.75, including $16.5M of IEEPA tariff refunds
  • $350M share repurchases since July 1, covering 2.7M shares at $128.96 average; $400M remains authorized
  • OEM sale generated $1.25B after-tax proceeds, supporting $700M debt repayment and revolving borrowings reduction; remaining divestiture targets year-end closing, potentially extending into 2027

Item EX-99.2 · Exhibit EX-99.2

  • Q3 adjusted EPS $2.63, up 39.2% year over year, supported by higher margins, lower interest expense, fewer shares and tariff refunds
  • OEM divestiture closed for $1.5B proceeds, $1.25B after tax, funding planned debt reduction and share repurchases
  • Q3 pro forma constant-currency revenue grew 3.0%, with Vascular up 4.6%, Interventional up 0.2% and Surgical up 5.1%
  • FY26 adjusted EPS guidance raised to $7.50-$7.75, while constant-currency revenue growth remains 3.5%-4.5%
  • Capital return includes $1B buyback and ~$800M debt reduction, with $400M repurchase authorization remaining

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teleflex Inc 8-K filings

Get the next TFX 8-K as it lands

Follow TFX for push alerts, or ask the research agent what this filing means.